OmniAb
illustrative antibody deal structure profile a profile | OmniAb
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
22 of 27
Similar slides by OmniAb
See diffirences between slides (animation)
Investor Presentation
August 2023
illustrative antibody deal structure profile a profile | OmniAb
Investor Presentation
May 2023
illustrative antibody deal structure profile a profile | OmniAb
Investor Conference
November 2022
illustrative antibody deal structure profile a profile | OmniAb
Related slides by other companies
Chimerix
Investor Presentation
August 2023
deal term summary emergent is an experienced company collaborating with government agencies to protect public health terms summary million received at closing in up to an additional million in potential procurement milestones royalty on future gross profit with volumes above million courses of therapy royalty of all international gross profit up to an additional million in development milestones a oral suspension tablets tembe me | Chimerix
Kiromic BioPharma
Investor Presentation
May 2023
upcoming milestones authorization to evaluate in non small cell lung cancer may beginning of first in human trial activation for data results from first patient in clinical trial by end of initiation of clinical trials expansion cohort submission of new for and | Kiromic BioPharma
Exscientia
Results
March 2024
partnership highlights milestones | Exscientia
Equillium
Investor Presentation
August 2023
milestones | Equillium
Other recent decks by OmniAb
See all presentations (10 decks)
Results
November 2024
Results
March 2024
Results
August 2023
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights